高级检索
当前位置: 首页 > 详情页

miR-140-3P Induces Chemotherapy Resistance in Esophageal Carcinoma by Targeting the NFYA-MDR1 Axis

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Shanxi Med Univ, Shanxi Acad Med Sci, Tongji Shanxi Hosp, Hosp 3,Canc Ctr,Shanxi Bethune Hosp, Taiyuan 030032, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430030, Peoples R China [3]Sun Yat Sen Univ, Canc Ctr, Affiliated Hosp 5, Zhuhai 519000, Peoples R China [4]Fudan Univ, Shanghai Canc Ctr, Shanghai 200032, Peoples R China [5]SHRM Biotechnol Pvt Ltd, Kolkata, W Bengal, India
出处:
ISSN:

关键词: Spinal injury Gene modulation Chemotherapy Treatment

摘要:
Esophageal carcinoma (EC) is recognized as the 6th most frequent carcinoma in China, with esophageal squamous cell carcinoma (ESCC) being the predominant histologic type. Currently, chemotherapy is one among the most important therapy modalities for patients with ESCC. However, resistance to chemotherapeutic drugs leads to limited treatment options and poor prognosis. In our study, the analysis of small RNA sequencing and digital gene expression (DGE) profiling was done to recognize the microRNAs (miRNAs) and key genes related with drug resistance in ESCC. It was noticed that the hsa-miRNA-140-3p (miR-140-3p) expression was considerably higher in drug-resistant cells than in sensitive cells. In addition, DGE identified target genes of miR-140-3p might perform key roles in ESCC. Furthermore, this work exhibited that miR-140-3p represents the nuclear transcription factor Y subunit alpha (NFYA) gene by targeting its 3'-untranslated regions. Such an interaction might influence the formation of the transcription factor NFY trimer, which in turn may inhibit the transcription of the multidrug resistance 1 gene and, ultimately, to multidrug resistance in ESCC. The inhibition of miR-140-3p decreased resistance to oxaliplatin in EC. Therefore, miR-140-3p may serve as a molecular marker for treatment response, efficacy, and prognosis of chemotherapy in ESCC patients.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 3 区 工程技术
小类 | 4 区 生化与分子生物学 4 区 生物工程与应用微生物
最新[2025]版:
大类 | 3 区 生物学
小类 | 3 区 生物工程与应用微生物 4 区 生化与分子生物学
JCR分区:
出版当年[2021]版:
Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
最新[2023]版:
Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者单位: [1]Shanxi Med Univ, Shanxi Acad Med Sci, Tongji Shanxi Hosp, Hosp 3,Canc Ctr,Shanxi Bethune Hosp, Taiyuan 030032, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430030, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Shanxi Med Univ, Shanxi Acad Med Sci, Tongji Shanxi Hosp, Hosp 3,Canc Ctr,Shanxi Bethune Hosp, Taiyuan 030032, Peoples R China [2]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Canc Ctr, Wuhan 430030, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:589 今日访问量:0 总访问量:441 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)